Trials / Completed
CompletedNCT00040599
Safety Study of 90Y-hMN14 to Treat Colorectal Cancer
A Phase I/II Study of Radioimmunotherapy With 90Y-Humanized MN-14 IgG Administered as a Single Dose to Patients With Refractory Metastatic/Recurrent Colorectal Carcinomas
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 72 (planned)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to determine the safety of 90Y-hMN14 at different dose levels in the treatment of colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | hMN14 (labetuzumab) |
Timeline
- Start date
- 2000-01-01
- Completion
- 2004-01-01
- First posted
- 2002-07-03
- Last updated
- 2021-08-19
Locations
10 sites across 5 countries: United States, Germany, Hungary, Sweden, Switzerland
Source: ClinicalTrials.gov record NCT00040599. Inclusion in this directory is not an endorsement.